Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies

Shots:

• Artios to receive $20M upfront in addition to near term research funding to support the collaboration and is eligible to receive $1.3B in discovery, development, regulatory, and sales milestones along with royalties on net sales of products
• Novartis to utilize Artios’ discovery platform to discover and validate DDR targets to enhance its radioligand therapies, selects up to three exclusive DDR targets, and will additionally receive WW rights on these targets to be used with its RLT’s
• The collaboration does not include Artios’ lead programs (ART0380 and ART4215), currently under clinical development

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Artios Pharma